Abstract
The objective of this multicenter phase II study was to evaluate the activity of docetaxel in previously untreated small cell lung cancer. Fourteen patients were treated at a dose of 75 mg/m2 intravenously every three weeks. Of the 12 patients evaluable for response, one had a partial response for a duration of 12 weeks for a response rate of 8.3%. Toxicity was mild. We conclude that docetaxel has, at the dose given in this study, little activity in previously untreated small cell lung cancer.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Docetaxel
-
Drug Administration Schedule
-
Female
-
Humans
-
Injections, Intravenous
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Paclitaxel / adverse effects
-
Paclitaxel / analogs & derivatives*
-
Paclitaxel / therapeutic use
-
Taxoids*
Substances
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Docetaxel
-
Paclitaxel